Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Share :
Published: 3 Oct 2023
Views: 119
Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Dr Gabriele Casirati speaks to ecancer about his study which showed that epitope editing enables targeted immunotherapy of acute myeloid leukaemia.

The study reported that tumour-associated antigens shared by normal tissue can be precisely modified, resulting in selective resistance to targeted immunotherapies and generating artificial leukaemia-restricted antigens.

The aim of this study was that high-risk patients who do not fare well with first-line treatments could receive an edited transplant, and after the transplant, they have the possibility to receive a very potent CART cell therapy without having the risk of on-target toxicity.

Dr Gabriele Casirati discusses the methodology and the results of the study in detail. He notes that epitope editing is a really promising new technology that can definitely be translated into clinical practice.

Read the full story here.